CPC A61K 39/0011 (2013.01) [A61K 9/0019 (2013.01); A61K 39/395 (2013.01); C07K 16/30 (2013.01); C12N 5/0639 (2013.01); C12N 5/0645 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/575 (2013.01); C12N 2500/44 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2301 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/24 (2013.01); C12N 2501/25 (2013.01)] | 16 Claims |
1. A method of stimulating an immune response against a cancer cell-specific antigen in an identified cancer in a subject at risk of having the identified cancer, comprising:
co-administering to the subject an immunologically effective amount of
(a) a whole cancer cell antigen-loaded dendritic cells isolated from a first population of white blood cells cultured under a first set of culture conditions, and
(b) a whole cancer cell antigen-loaded macrophages isolated from a second population of white blood cells cultured under a second set of culture conditions,
wherein the white blood cells are each autologous to the subject, and the whole cancer cell antigen-loaded dendritic cells and the whole cancer cell antigen-loaded macrophages have internalized by phagocytosis a whole cancer cell of the identified cancer in vitro.
|